Financial giants have made a conspicuous bullish move on Novo Nordisk ( NVO ). Our analysis of options history for Novo Nordisk ( NVO ) revealed 26 unusual trades.

Delving into the details, we found 61% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $1,362,610, and 16 were calls, valued at $832,150.

What's The Price Target?

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $80.0 to $175.0 for Novo Nordisk ( NVO ) during the past quarter.

Volume & Open Interest Development

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Novo Nordisk's ( NVO ) options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Novo Nordisk's ( NVO ) significant trades, within a strike price range of $80.0 to $175.0, over the past month.

Novo Nordisk 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

About Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk ( NVO ) is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk's Current Market Status

With a volume of 2,428,026, the price of NVO is up 0.49% at $129.4.

RSI indicators hint that the underlying stock may be approaching overbought.

Next earnings are expected to be released in 38 days.

Professional Analyst Ratings for Novo Nordisk

A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $160.0.

An analyst from Cantor Fitzgerald has decided to maintain their Overweight rating on Novo Nordisk ( NVO ), which currently sits at a price target of $160.

An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk ( NVO ) options trades with real-time alerts from Benzinga Pro.